- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04598425
Cognitive Behavioral Therapy for Insomnia (CBTi) in Patients With Mental Illness
September 29, 2022 updated by: Kåre Osnes, Diakonhjemmet Hospital
Insomnia is common in patients with co-morbid mental illness and sleeping difficulties is a frequent complaint in most psychological disorders.
Mental illness may cause sleep problems, however, sleep problems like insomnia, may also cause or exacerbate mental illness.
Insomnia may aggravate symptoms of depression, anxiety and fatigue, and reduce daily functioning in patients with co-morbid insomnia and mental illness.
This project aims to evaluate a course offered to patients with insomnia and mental illness at Diakonhjemmet Hospital.
The course is based on cognitive behavioral therapy, a documented treatment for insomnia.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
40
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Oslo, Norway
- Department of Psychiatry, Diakonhjemmet Hospital, Oslo, Norway
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 63 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Men and women over 18 years with insomnia and co-morbid mental illness.
- Is a patient and receiving treatment for mental illness at Department of Psychiatry, Diakonhjemmet Hospital, at time of referral to the course
Exclusion Criteria:
- Unable to provide informed consent
- Unable to read and/or understand Norwegian
- Unable to complete a survey
- Severe mental disorder, e.g. schizophrenia and bipolar disorder type I
- Mental retardation or dementia
- Known substance abuse
- Other sleep disorder, e.g. narcolepsy and hypersomnia
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cognitive behavioral therapy for insomnia (CBTi)
|
Patients will undergo a 7 sessions course in cognitive behavioral therapy for insomnia.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in severity of insomnia
Time Frame: At baseline (before first session), at session 6 (last ordinary session, 5-7 weeks after baseline), at session 7 (2 months after last ordinary session) and 6 months after completing the course.
|
All patients included in the study will be asked to complete the Insomnia Severity Index (ISI; Minimum value = 0; Maximum value = 4. Higher scores mean worse outcome) to assess for any changes in symptoms of insomnia.
|
At baseline (before first session), at session 6 (last ordinary session, 5-7 weeks after baseline), at session 7 (2 months after last ordinary session) and 6 months after completing the course.
|
Change in symptoms of insomnia
Time Frame: At baseline (before first session), at session 6 (last ordinary session, 5-7 weeks after baseline), at session 7 (2 months after last ordinary session) and 6 months after completing the course.
|
All patients included in the study will be asked to complete the Bergen Insomnia Scale ( Minimum value = 0; Maximum value = 7.
Higher scores mean worse outcome) to assess for any changes in symptoms of insomnia.
|
At baseline (before first session), at session 6 (last ordinary session, 5-7 weeks after baseline), at session 7 (2 months after last ordinary session) and 6 months after completing the course.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in sleep efficiency
Time Frame: Calculations of sleep efficiency at baseline (before first session), at session 6 (last ordinary session, 5-7 weeks after baseline), at session 7 (2 months after last ordinary session) and 6 months after completing the course, will be compared.
|
All patients included in the study will be asked to keep a sleep diary for the whole duration of the course.
Sleep efficiency will be calculated based on the sleep diary.
|
Calculations of sleep efficiency at baseline (before first session), at session 6 (last ordinary session, 5-7 weeks after baseline), at session 7 (2 months after last ordinary session) and 6 months after completing the course, will be compared.
|
Change in dysfunctional beliefs and attitudes about sleep
Time Frame: At baseline (before first session), at session 6 (last ordinary session, 5-7 weeks after baseline), at session 7 (2 months after last ordinary session) and 6 months after completing the course.
|
All patients included in the study will be asked to complete the Dysfunctional Beliefs and Attitudes about Sleep scale (DBAS-16; Minimum = 0; Maximum = 10.
Higher values mean worse outcome) to assess for any changes in dysfunctional beliefs and attitudes about sleep.
|
At baseline (before first session), at session 6 (last ordinary session, 5-7 weeks after baseline), at session 7 (2 months after last ordinary session) and 6 months after completing the course.
|
Change in daytime rumination about tiredness and negative consequences of lack of sleep
Time Frame: At baseline (before first session), at session 6 (last ordinary session, 5-7 weeks after baseline), at session 7 (2 months after last ordinary session) and 6 months after completing the course.
|
All patients included in the study will be asked to complete the Daytime Insomnia Symptom Response Scale (DISRS; Minimum = 1; Maximum = 4. Higher values mean worse outcome) to assess for any changes in rumination about insomnia symptoms.
|
At baseline (before first session), at session 6 (last ordinary session, 5-7 weeks after baseline), at session 7 (2 months after last ordinary session) and 6 months after completing the course.
|
Change in compliance with sleep hygiene measures
Time Frame: At baseline (before first session), at session 6 (last ordinary session, 5-7 weeks after baseline), at session 7 (2 months after last ordinary session) and 6 months after completing the course.
|
All patients included in the study will be asked to complete the Sleep Hygiene Index (SHI-13; Minimum value = 1; Maximum value = 5.
Higher values mean worse outcome) to assess for any changes in compliance with sleep hygiene measures.
|
At baseline (before first session), at session 6 (last ordinary session, 5-7 weeks after baseline), at session 7 (2 months after last ordinary session) and 6 months after completing the course.
|
Change in symptoms of depression
Time Frame: At baseline (before first session), at session 6 (last ordinary session, 5-7 weeks after baseline), at session 7 (2 months after last ordinary session) and 6 months after completing the course.
|
All patients included in the study will be asked to complete the Patient Health Questionnaire-9 (PHQ-9; Minimum value = 0; Maximum value = 3.
Higher values mean worse outcome) to assess for any changes in symptoms of depression.
|
At baseline (before first session), at session 6 (last ordinary session, 5-7 weeks after baseline), at session 7 (2 months after last ordinary session) and 6 months after completing the course.
|
Change in symptoms of anxiety
Time Frame: At baseline (before first session), at session 6 (last ordinary session, 5-7 weeks after baseline), at session 7 (2 months after last ordinary session) and 6 months after completing the course.
|
All patients included in the study will be asked to complete the Generalized Anxiety Disorder Scale-7 (GAD-7; Minimum value = 0; Maximum value = 3.
Higher values mean worse outcome) to assess for any changes in symptoms of anxiety.
|
At baseline (before first session), at session 6 (last ordinary session, 5-7 weeks after baseline), at session 7 (2 months after last ordinary session) and 6 months after completing the course.
|
Change in somatic symptoms
Time Frame: At baseline (before first session), at session 6 (last ordinary session, 5-7 weeks after baseline), at session 7 (2 months after last ordinary session) and 6 months after completing the course.
|
All patients included in the study will be asked to complete the Somatic Symptom Scale-9 (SSS-8; Minimum value = 0; Maximum value = 4. Higher value mean worse outcome) to assess for any changes in somatic symptom burden.
|
At baseline (before first session), at session 6 (last ordinary session, 5-7 weeks after baseline), at session 7 (2 months after last ordinary session) and 6 months after completing the course.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 1, 2018
Primary Completion (Actual)
August 31, 2021
Study Completion (Actual)
August 31, 2021
Study Registration Dates
First Submitted
July 6, 2020
First Submitted That Met QC Criteria
October 16, 2020
First Posted (Actual)
October 22, 2020
Study Record Updates
Last Update Posted (Actual)
September 30, 2022
Last Update Submitted That Met QC Criteria
September 29, 2022
Last Verified
September 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 00058 (PVO DS)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sleep Disorder
-
Matrouh UniversitySuez Canal University; Beni-Suef University; University of Bisha, Saudia ArabiaCompletedSleep Disorder | Sleep Hygiene | Sleep Disorder; Insomnia Type | Sleep Disorder in Elderly | Sleep Disorder, Mental Health | Sleep Disorders, Physical HealthEgypt
-
Johns Hopkins UniversityNational Institute on Drug Abuse (NIDA)CompletedSleep Disorder | Diarrhea | Anxiety Disorders | Insomnia | Sleep Initiation and Maintenance Disorders | Anxiety | Sleep Disturbance | Gastrointestinal Dysfunction | Heartburn | Caffeine | Caffeine Withdrawal | Caffeine; Sleep Disorder | Caffeine Dependence | Caffeine-Induced Anxiety Disorder | Caffeine-Induced Sleep... and other conditionsUnited States
-
Johannes Gutenberg University MainzRecruitingSleep Disorder | Restless Legs Syndrome | Insomnia | Sleep Apnea | Narcolepsy | Idiopathic Hypersomnia | Somnambulism | Sleep Disorder Parasomnia | REM Behavior DisorderGermany
-
Yale UniversityCompletedCircadian Rhythm Sleep Disorder, UnspecifiedUnited States
-
The University of Texas Health Science Center,...Active, not recruitingRapid Eye Movement Sleep Behavior DisorderUnited States
-
Merck Sharp & Dohme LLCCompletedDyssomnias | Sleep Disorders | Mental Disorder | Sleep Initiation and Maintenance Disorder; Elderly | Sleep Disorder, Intrinsic
-
Vanda PharmaceuticalsRecruitingSleep Disorder | Sleep Disturbance | Autism Spectrum Disorder | Neurological DisorderUnited States
-
Assistance Publique Hopitaux De MarseilleAix Marseille UniversitéRecruitingREM Sleep Behaviour DisorderFrance
-
Yale UniversityNational Heart, Lung, and Blood Institute (NHLBI)RecruitingCritical Illness | Sleep Deprivation | Circadian Rhythm Sleep Disorder, UnspecifiedUnited States
-
Massachusetts General HospitalRecruitingRapid Eye Movement Sleep Behavior DisorderUnited States
Clinical Trials on Cognitive behavioral therapy for insomnia (CBTi)
-
VA Office of Research and DevelopmentCompletedInsomnia | Gulf War IllnessUnited States
-
Diakonhjemmet HospitalActive, not recruitingSleep Disorder | Insomnia | Sleep Initiation and Maintenance Disorders | Chronic Disease | Sleep Disturbance | Insomnia Chronic | Insomnia Due to Medical Condition | Insomnia, PsychophysiologicalNorway
-
University of MichiganCompleted
-
Durham VA Medical CenterTerminatedHypertension | Cardiovascular Disease | Insomnia | Posttraumatic Stress DisorderUnited States
-
Emory UniversityNational Institute on Aging (NIA)RecruitingDementia | Sleep DisturbanceUnited States
-
Penn State UniversityUniversity of Arizona; Proactive Life IncCompletedInsomnia | Alzheimers Disease Related DementiasUnited States
-
University of ArizonaRecruitingSleep Initiation and Maintenance DisordersUnited States
-
VA Pittsburgh Healthcare SystemVA Office of Research and DevelopmentCompleted
-
Oregon State UniversityMonash University; Stanford University; American Academy of Sleep MedicineRecruitingSleep Initiation and Maintenance Disorders | Circadian Rhythm Sleep-Wake Disorders, Shift Work TypeUnited States
-
Henry Ford Health SystemCompleted